Year: 2026

Introduction For exporters targeting Kenya’s healthcare market, the Kenya Essential Medicines List (KEML) is a key reference point alongside PPB product registration. Where PPB registration determines whether a specific product can legally enter the market, the KEML provides a reference for medicines prioritized within Kenya’s public health system and Universal Health Coverage (UHC) programs. This guide covers what the KEML is, how it’s structured, and how exporters can use it to align product strategy with real market demand. What Is the Kenya Essential Medicines List (KEML)? Kenya developed its first Essential Medicines List in 1981, making it one of the longer-standing essential medicines programs on the continent. The KEML is a key tool used to promote access to essential medicines, and through correct selection, procurement, and use, to achieve maximum therapeutic benefit and optimize patient outcomes under Universal Health Coverage. The rationale for listing medicines in the KEML is informed by the WHO Model List of Essential Medicines, which countries adapt to their own healthcare needs and context., covering both adult and pediatric formulations, which countries then adapt to their own context. The KEML is reviewed and updated periodically, so exporters should always refer to the latest official edition when assessing product opportunities in Kenya. depending on the extent of accumulated changes needed, with urgent amendments communicated through established coordination channels in the interim. Important distinction for exporters: the KEML is separate from PPB product registration. PPB registration and other applicable regulatory approvals address whether a pharmaceutical product can legally enter the Kenyan market, while the KEML provides guidance on medicines considered essential and prioritized within the healthcare system Key Therapeutic Categories on the KEML The current KEML categorizes medicines into 35 therapeutic groups selected based on public health needs and priorities, with recent editions adding coverage for non-communicable diseases and neglected tropical diseases. The major categories relevant to export planning include: 1. Anti-Infective Medicines The KEML classifies antibiotics using the WHO‘s Access, Watch, Reserve framework, guiding antimicrobial resistance policy a structure exporters should be aware of when positioning antibiotic products. 2. Antimalarials A consistently prioritized category given malaria’s continued burden across much of Kenya. (WHO – Malaria) 3. Anti-HIV / Antiretroviral Medicines Reflecting Kenya’s substantial national HIV treatment program under its UHC framework. 4. Medicines for Non-Communicable Diseases An increasingly important category covering cardiovascular disease, diabetes, and other chronic conditions as non-communicable diseases (NCDs) become a growing public health priority. 5. Medicines for Pain and Palliative Care A distinct, standalone category reflecting growing attention to palliative care access. 6. Anaesthetics and Perioperative Medicines Core hospital-level medicines required across Kenya’s healthcare facility network. 7. Neglected Tropical Disease Medicines A category specifically expanded in recent revisions, addressing diseases with historically limited treatment access. 8. Maternal, Newborn, and Child Health Medicines Aligned with WHO guidance on essential medicines for children, covering treatment needs specific to pediatric patients. Why the KEML Matters for Exporters ✔ Signals public procurement priority Products aligned with KEML categories can help exporters identify therapeutic areas relevant to Kenya’s public-sector procurement and healthcare supply planning. ✔ Guides product portfolio decisions Exporters can use the KEML’s 35 therapeutic groups to identify where their existing catalog aligns — or has gaps — relative to Kenyan demand. ✔ Antibiotic classification matters for positioning Given the KEML’s AWaRe-based antibiotic classification, exporters supplying antimicrobials should understand where their products fall within that framework when engaging Kenyan buyers. ✔ Distinct from, but complementary to, PPB registration Inclusion in the KEML does not replace the applicable PPB registration and regulatory requirements for pharmaceutical products entering Kenya. How Exporters Can Use This Information ✔ Map your product portfolio against the KEML’s 35 therapeutic groups to spot supply opportunities ✔ Prioritize PPB registration for products in high-priority KEML categories, particularly NCD and neglected tropical disease medicines given their recent expansion ✔ Understand your antibiotic products’ AWaRe classification before engaging institutional buyers ✔ Track KEML revision cycles, since the list is reviewed periodically and category priorities shift accordingly Conclusion The Kenya Essential Medicines List offers a clear window into what Kenya’s healthcare system — increasingly shaped by its Universal Health Coverage agenda — actually needs and procures. Exporters who align product strategy with KEML priorities, on top of securing PPB registration, are better positioned for the county and national tender channels that drive a large share of Kenyan pharmaceutical demand. Partnering with an experienced pharma export company in India familiar with both PPB requirements and KEML priorities helps align product strategy with actual market demand rather than guesswork.

Introduction For any exporter or manufacturer targeting Nigeria’s healthcare market, understanding the Nigeria Essential Medicines List (NEML) is just as important as understanding NAFDAC registration itself. The NEML shapes what public hospitals, primary healthcare centers, and government procurement programs actually buy — making it a useful reference point for product strategy, not just a regulatory document. This guide covers what the NEML is, how it’s structured, and what it means for pharmaceutical exporters supplying the Nigerian market. What Is the Nigeria Essential Medicines List (NEML)? The Nigeria Essential Medicines List is a tool used in the country’s healthcare delivery system, containing medicines considered the most effective, safe, and cost-effective options for priority health conditions, consistent with the broader WHO essential medicines framework. It is developed in line with the World Health Organization’s Model List of Essential Medicines, alongside Nigeria’s own Standard Treatment Guidelines and NAFDAC’s approved product list. The list is periodically revised, so exporters should always refer to the latest official NEML edition when planning their product portfolio for Nigeria. Important distinction for exporters: the NEML is not the same thing as NAFDAC product registration. NAFDAC registration is required for regulated pharmaceutical products to be legally imported, sold, or distributed in Nigeria. The NEML, by contrast, reflects which categories of medicines Nigeria’s public health system prioritizes for procurement — a product can be NAFDAC-registered without appearing on the NEML, and vice versa. Key Therapeutic Categories on the NEML The NEML is organized by therapeutic category, broadly mirroring the WHO Model List structure. The major categories relevant to export planning include: 1. Anti-Infective Medicines Antibiotics, antifungals, and antiviral agents addressing infectious diseases are important components of essential medicines lists. For antibiotics, the WHO AWaRe classification provides a framework for monitoring antibiotic use and supporting antimicrobial stewardship. 2. Antimalarials Given malaria’s continued impact on public health in Nigeria, this category remains a priority procurement area for government and NGO buyers alike. 3. Anti-HIV / Antiretroviral Medicines Reflecting Nigeria’s large national HIV treatment program, ARV medicines form a significant and consistently procured category. 4. Tuberculosis and Leprosy Medicines Core first-line and combination TB treatments feature prominently, tied to Nigeria’s national TB control program. 5. Maternal and Child Health Medicines Medicines supporting maternal care, safe delivery, and pediatric treatment — a growing priority area given Nigeria’s public health focus on maternal and infant mortality reduction. 6. Cardiovascular and Chronic Disease Medicines Growing in relative importance as non-communicable disease burden rises alongside infectious disease priorities. 7. Pain Management and Anesthesia Medicines Standard analgesics and anesthetic agents used across the public hospital system. 8. Controlled Medicines A specifically regulated subset covering narcotics and psychotropic substances, subject to additional oversight beyond standard NEML inclusion, in line with Nigeria’s obligations under international drug control conventions. Why the NEML Matters for Exporters ✔ Signals procurement priorityProducts aligned with essential medicines priorities can help exporters understand public-sector procurement and supply requirements when developing a Nigeria-focused product portfolio. ✔ Guides product portfolio decisionsExporters building out a Nigeria-focused catalog can use NEML categories to prioritize which products to register and stock first. ✔ Distinct from, but complementary to, NAFDAC registrationA strong NEML-aligned portfolio still requires full NAFDAC registration per product — the two processes serve different purposes and both matter. ✔ Referenced in tender and procurement documentationPublic sector and NGO buyers frequently structure tenders around NEML categories and specifications, making familiarity with the list useful during bid preparation. How Exporters Can Use This Information ✔ Cross-reference your product portfolio against the current NEML to identify potential supply gaps and priority therapeutic categories.✔ Prioritize NAFDAC registration for products that also appear in high-procurement NEML categories✔ Reference NEML alignment in marketing and tender materials aimed at public sector and NGO buyers✔ Stay current on NEML revisions, since the list is periodically updated and category priorities can shift Conclusion The Nigeria Essential Medicines List is a useful lens for understanding what the country’s healthcare system actually needs and procures — distinct from, but closely related to, the NAFDAC registration process every exporter must go through regardless. Exporters who align their product strategy with NEML priorities, while securing the required NAFDAC registration, can make more informed decisions when targeting Nigeria’s public-sector and institutional pharmaceutical market. Partnering with an experienced pharma export company in India familiar with both NAFDAC requirements and NEML priorities helps align product strategy with actual market demand rather than guesswork.

Introduction India supplies a significant share of the affordable generic medicines used across African healthcare systems, from public hospitals to private pharmacies and NGO-run clinics. Given the continent’s disease burden and limited local manufacturing capacity, African countries rely heavily on imported medicines to keep treatment accessible and affordable. This list of generic medicines exported to Africa covers the therapeutic categories in highest demand across markets like Nigeria, Kenya, and Ghana, along with the formulations and pack sizes distributors typically order. Why Generic Medicines Dominate African Pharma Imports Generic medicines can provide effective treatment at lower cost when they meet appropriate quality, safety and efficacy standards, making them an important part of procurement for public health systems, NGOs, and private distributors across Africa. Key drivers of demand: High burden of infectious disease across Sub-Saharan Africa Limited local pharmaceutical manufacturing capacity relative to population healthcare needs Public procurement systems and NGO buyers prioritizing cost-effective treatment Strong reliance on imports, with the continent sourcing the large majority of its pharmaceutical and medicinal needs from outside Africa Top Categories of Generic Medicines Exported to Africa 1. Anti-Infectives and Antibiotics The single largest category by volume, driven by the high prevalence of bacterial and infectious disease across the region. Amoxicillin — bacterial infections, commonly supplied in capsule strips and oral suspensions Azithromycin — respiratory infections, typically packed in short-course blister strips Ciprofloxacin — UTIs and skin infections, tablet strips Doxycycline — broad-spectrum antibiotic, capsule form Metronidazole — anaerobic and parasitic infections, tablets and IV formulations 2. Antimalarials Given malaria’s continued burden across much of Sub-Saharan Africa, antimalarials remain a consistently high-volume export category. Artemether-Lumefantrine combination therapies Chloroquine and hydroxychloroquine (regional demand varies by resistance patterns) Sulfadoxine-pyrimethamine for preventive therapy programs 3. Anti-HIV / Antiretroviral Medicines African markets, particularly those with large public HIV treatment programs, remain important users of quality-assured antiretroviral medicines. Tenofovir-based combination therapies Efavirenz combinations Lamivudine and Nevirapine formulations 4. Tuberculosis Medicines TB remains a significant public health priority across much of Africa, and Indian generics form a core part of national TB treatment programs. Isoniazid Rifampicin Ethambutol and Pyrazinamide combinations 5. Pain Management and Anti-Inflammatory Medicines High-volume, everyday-use categories supplied to hospitals, clinics, and retail pharmacies alike. Paracetamol — tablets, syrups, and IV formulations Ibuprofen — tablets and suspensions Diclofenac — tablets and injectables 6. Pediatric Formulations Child healthcare products are a distinct and steadily growing export category, given high birth rates and pediatric disease burden across the region. Pediatric antibiotic syrups Oral rehydration and nutritional supplements Pediatric drops and suspensions for fever and pain 7. Oncology Medicines A smaller but growing category as African healthcare systems expand cancer treatment access, with demand concentrated in urban hospital networks. Generic chemotherapy agents Supportive care medicines for oncology patients 8. Injectables and Critical Care Formulations Hospitals and healthcare institutions import significant volumes of injectable medicines for critical and emergency care. IV antibiotics Injectable pain management and anesthesia support drugs Emergency care formulations What Distributors and Buyers Typically Look For ✔ WHO-GMP compliance or equivalent quality standards for the manufacturing facility ✔ Product registration status with the relevant national regulator, such as NAFDAC, PPB, or FDA Ghana ✔ Competitive, consistent pricing across order volumes ✔ Reliable supply continuity, since stockouts in these categories have direct public health impact ✔ Appropriate pack sizes for the local retail and institutional buying patterns in each market For pharmaceutical exporters and distributors, ensuring that medicines meet established regulatory and quality requirements is essential, particularly given the risks associated with substandard and falsified medical products. Conclusion The list of generic medicines exported to Africa is shaped directly by the continent’s disease burden — anti-infectives, antimalarials, antiretrovirals, and TB medicines dominate volume, while pediatric and oncology categories represent the fastest-growing segments. For exporters, matching product portfolio to this demand pattern, backed by WHO-GMP certification and registered status in target markets, is what turns a generic export into a repeat institutional buyer relationship. Partnering with an experienced pharmaceutical exporters in India with a broad, WHO-GMP certified generics portfolio makes it easier to meet the full range of demand across African markets rather than a narrow product slice.